Logotype for Dimed S.A. Distribuidora de Medicamentos

Dimed (PNVL3) Q2 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Dimed S.A. Distribuidora de Medicamentos

Q2 2026 earnings summary

25 Aug, 2026

Executive summary

  • Net revenue for the first half of 2026 reached R$2,958.8 million, up 15% year-over-year, with net income of R$63.6 million, a 26% increase compared to the same period in 2025.

  • Retail gross revenue in 2Q26 was R$1.63 billion, up 15.8% year-over-year, driven by digital acceleration and robust performance across all categories.

  • Digital sales reached a record 33.7% of retail gross revenue, with app sales surging 155.9%.

  • Same-store sales grew 13.5% and mature store sales 11.4%, both above inflation.

  • Seven new stores were opened in Q2 2026, totaling 31 new stores in the last 12 months, supporting continued expansion.

Financial highlights

  • Consolidated net revenue: R$2,958.8 million in H1 2026 vs. R$2,572.4 million in H1 2025.

  • Adjusted EBITDA rose 26.4% to R$88.5 million, and adjusted net income increased 39.1% to R$38.9 million.

  • Earnings per share: Basic R$0.43, diluted R$0.42 for H1 2026.

  • Cash and cash equivalents at period end: R$59.9 million; short-term investments: R$235.2 million.

  • Free cash flow: R$1.9 million; sixth consecutive quarter of positive generation.

Outlook and guidance

  • Management does not expect material impacts from the ongoing Brazilian tax reform in 2026.

  • Continued focus on digital expansion, store productivity, and margin improvement.

  • Plans to accelerate investments in store openings and renovations in the second half of 2026.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more